Biotechnology

HENLIUS

Hengrui Medicine's HLX43 Completes First Patient Dosing in EU for NSCLC Phase 2 Trial

Hengrui Medicine's HLX3902 Approved in Australia to Initiate Phase I Trial for Prostate Cancer

Fosun Pharma's Hengrui Medicine Receives Approval for Phase I Clinical Trial of HLX48 for Solid Tumors

Fosun Hanlin Bio-Technology Established as Wholly-owned Subsidiary of Hengli on May 18

Fuzhonghannling's HLX48 Bispecific Antibody Drug Receives Approval for Clinical Trials in Australia

Fuzhong Hansheng Completes First Patient Dosing in HLX97 Phase 1 Clinical Trial

Shanghai Henlius Initiates Clinical Trial of HLX97 for Advanced Solid Tumors

Hengrui's PD-1 antibody serplulimab approved by the European Commission for new cancer indications

Fosun Pharma Subsidiary Approved for Phase I Clinical Trial of HLX05-N for Metastatic Colorectal Cancer in the US

Fulihannlin's HLX43 Clinical Trial Granted Implied Approval in Japan

Shanghai Hengrui Pharmaceuticals Initiates International Phase 2/3 Clinical Trial for HLX43

Fugong Hanlin Completes First Patient Dosing for HLX3901 in Phase 1 Clinical Trial for Small Cell Lung Cancer

EC Approves Henlius and Organon's POHERDY®

Futilei Hanlin's HLX07 and Hansizang Combined Therapy for Advanced Squamous Non-Small Cell Lung Cancer Phase 2/3 Clinical Trials Approved

Fosun Pharma's Subsidiary Approved to Conduct Clinical Trials for HLX05-N in Metastatic Colorectal Cancer Treatment

Ful ひ宏汉霖 Completes First Dose Administration in Phase 1 Clinical Trial for HLX319

Fosun Pharma's Subsidiary's Hanlikang New Indication Approved

Fanhong Hanlin Announces 2025 Annual Report, Facing Pressure for Innovation Transformation

Fosun Pharma's Subsidiary Obtains Approval for HLX319 Phase I Clinical Trials for Breast Cancer

Fosun Pharma's Subsidiaries Receive Approval for Two Drug Clinical Trials

I.CENTURY HLDG

RIVERINE CHINA

KOS TALENT GP

CHINA CBS INTL

NATURE ENERGY T

DIGIT HOLLYWOOD

REDCO HEALTHY

ZXZN QI-HOUSE

ASIA PIONEER

HUISHENG INTL

02696

Shanghai Henlius Biotech, Inc. has received Australian approval for a phase 1 clinical trial of HLX48, a bispecific antibody-drug conjugate targeting EGFR and c-MET for advanced solid tumors. This therapy aims to combine targeted drug delivery with immune mechanisms to inhibit tumor growth. If successful, it would be the first bispecific ADC against both targets. The company warns of the risks in development and commercialization. Analysts rate the stock as a Buy with a price target of HK$99.78, and the current market cap is HK$39.13B.

Tip Ranks

Henlius Wins Australian Nod for First-in-Class Bispecific Cancer ADC Trial

516500

159849

520880

159992

510660

588250

159316

512290

Shanghai Henlius Biotech, Inc. has received EU approval for two new uses of its anti-PD-1 antibody serplulimab (HETRONIFLY) for treating esophageal squamous cell carcinoma and non-squamous non-small cell lung cancer. This approval, supported by phase 3 data, enhances Henlius's oncology portfolio and commercial prospects in Europe and India through its partnership with Intas Pharmaceuticals. The stock is rated a Buy with a target price of HK$99.78.

ChinaAMC CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Guotai CSI Bio-medicine ETF

Henlius Wins EU Approval for Two New Serplulimab Cancer Uses

Shanghai Henlius Biotech, Inc. has received FDA approval to conduct a phase 1 clinical trial for HLX05-N, a biosimilar to cetuximab, aimed at treating metastatic colorectal cancer. This follows prior approval from China's National Medical Products Administration. The company anticipates entering a lucrative oncology biosimilar market, with global sales projected at USD 1.66 billion by 2025. Analysts rate the stock as a Buy with a target price of HK$99.78, although successful development is not guaranteed.

First Trust NYSE Arca Biotech Index Fd

Henlius Wins FDA Nod to Begin U.S. Trial of Cetuximab Biosimilar HLX05-N

Shanghai Henlius Biotech, Inc. has announced the grant of 810,000 share options and 810,000 restricted share units to 142 participants, including employees and service providers. This initiative aims to align incentives with long-term performance and market capitalization targets, enhancing talent retention and engagement. The company's focus on R&D and financial performance is crucial in the competitive biotech landscape. The latest analyst rating for Henlius stock (HK:2696) is a Buy, with a price target of HK$99.78, reflecting positive market sentiment.

Henlius Grants New Share Options and RSUs to Align Incentives With Performance

513700

516820

159506

512010

159859

159615

588130

Shanghai Henlius Biotech, Inc. has received Chinese regulatory approval to expand the indications for its rituximab biosimilar, HANLIKANG. The approval allows for two new combination therapies for adult patients with untreated and relapsed or refractory diffuse large B-cell lymphoma. This expansion enhances Henlius's oncology portfolio in a market valued at approximately RMB3.465 billion, providing more treatment options for patients. The stock is currently rated as a Buy with a price target of HK$99.78, reflecting positive market sentiment.

Penghua CSI HK Connect Health Care Composite ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Minsheng Royal CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund CSI 300 Health Care ETF

Bosera Hang Seng Health Care ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

China Southern Hang Seng Biotech ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Huaan Hang Seng Biotech ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Henlius Wins China Nod to Expand Indications for Rituximab Biosimilar HANLIKANG

Henlius Wins Key EMA Backing for Cancer Drug Serplulimab in Europe

Henlius Wins Key EMA Backing for Cancer Drug Serplulimab in Europe

Henliusannounced its 2025 annual results, marking its third consecutive year of profitability since 2023. The company reported revenues of 6.67 billion RMB, a 16.5% year-on-year increase, and a net profit of 827 million RMB. R&D investment rose by 35.4% to 2.49 billion RMB. International sales exceeded 200 million RMB, doubling from the previous year. The flagship product, serplulimab, generated 1.49 billion RMB in global sales, a 13.7% increase. Henlius aims to enhance its global biopharmaceutical model while continuing to deliver quality biological products to patients worldwide.

prnewswire

22:20 ETHenlius informa sus resultados de 2025: Crecimiento sostenido tanto en ingresos como en beneficios

HENLIUS(02696.HK)

Henlius Wins Australian Nod for First-in-Class Bispecific Cancer ADC Trial

Henlius Wins EU Approval for Two New Serplulimab Cancer Uses

Henlius Wins FDA Nod to Begin U.S. Trial of Cetuximab Biosimilar HLX05-N

Henlius Grants New Share Options and RSUs to Align Incentives With Performance

Henlius Wins China Nod to Expand Indications for Rituximab Biosimilar HANLIKANG

Henlius Wins Key EMA Backing for Cancer Drug Serplulimab in Europe

22:20 ETHenlius informa sus resultados de 2025: Crecimiento sostenido tanto en ingresos como en beneficios